Potential of azidothymidine to activate the HIV-1 promoter.
Azidothymidine (AZT) has been used for treatment of acquired immunodeficiency syndrome (AIDS), but a recent concord trial showed that it is ineffective for suppressing the development of AIDS. In this study, the effects of AZT on three cell lines transformed by pCD12 plasmid (human immunodeficiency virus-1 (HIV-1) promoter-chloramphenicol acetyltransferase) were examined. Results showed that AZT has the potential to activate the HIV-1 promoter.
Kurata
S
S
Department of Biochemical Genetics, Tokyo Medical and Dental University, Japan.
D001483:Base Sequence; D002461:Cell Line, Transformed; D015500:Chloramphenicol O-Acetyltransferase / Q000378:metabolism; D004247:DNA / Q000378:metabolism; D016325:HIV Long Terminal Repeat; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D008969:Molecular Sequence Data; D016328:NF-kappa B / Q000378:metabolism; D011401:Promoter Regions, Genetic / Q000187:drug effects*; D015215:Zidovudine / Q000494:pharmacology*
D016328:NF-kappa B; D015215:Zidovudine; D004247:DNA; D015500:Chloramphenicol O-Acetyltransferase